Abstract
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have